Literature DB >> 18434745

Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm.

Jeffrey A Jones1, John R Barbour, Robert E Stroud, Shenikqua Bouges, Shelly L Stephens, Francis G Spinale, John S Ikonomidis.   

Abstract

OBJECTIVE: Thoracic aortic aneurysms (TAAs) develop by a multifactorial process involving maladaptive signaling pathways that alter the aortic vascular environment. Transforming growth factor-beta (TGF-beta) has been implicated in regulating the structure and composition of the extracellular matrix by differential activation of various intracellular signaling pathways. However, whether and to what degree TGF-beta signaling contributes to TAA development remains unclear. Accordingly, the hypothesis that alterations in TGF-beta signaling occur during aneurysm formation was tested in a murine model of TAA.
METHODS: TAAs were surgically induced in mice (C57BL/6J) and aortas were analyzed at predetermined time points (1, 2, and 4 weeks post-TAA induction). Quantitative real-time PCR (QPCR) was performed to evaluate the expression of 84 relevant TGF-beta superfamily genes, and the protein levels of key signaling intermediates were measured by immunoblotting. Results were compared to unoperated reference control mice.
RESULTS: QPCR revealed increased expression of TGF-beta superfamily ligands (Gdf-2, -6, -7, Inhba), ligand inhibitors (Bmper, Chrd, Gsc), and transcriptional regulators (Dlx2, Evi1), among other genes (Cdkn2b, Igf1, IL-6). Protein levels of TGF-beta receptor(II), Smad2, Smad1/5/8, phospho-Smad1/5/8, and Smurf1 were increased from control values post-TAA induction. Both TGF-beta receptor(I) and Smad4 were decreased from control values, while ALK-1 levels remained unchanged.
CONCLUSIONS: These alterations in the TGF-beta pathway suggest a mechanism by which primary signaling is switched from a TGF-betaR(I)/Smad2-dependent response, to an ALK-1/Smad1/5/8 response, representing a significant change in signaling outcome, which may enhance matrix degradation. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434745      PMCID: PMC2574785          DOI: 10.1159/000127437

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  54 in total

Review 1.  BMP/GDF-signalling interactions during synovial joint development.

Authors:  P H Francis-West; J Parish; K Lee; C W Archer
Journal:  Cell Tissue Res       Date:  1999-04       Impact factor: 5.249

Review 2.  Thoracic and abdominal aortic aneurysms.

Authors:  Eric M Isselbacher
Journal:  Circulation       Date:  2005-02-15       Impact factor: 29.690

Review 3.  TGFbeta signaling: receptors, transducers, and Mad proteins.

Authors:  J Massagué
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

4.  Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family.

Authors:  N M Wolfman; G Hattersley; K Cox; A J Celeste; R Nelson; N Yamaji; J L Dube; E DiBlasio-Smith; J Nove; J J Song; J M Wozney; V Rosen
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

5.  Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm.

Authors:  David C Paik; Chenzhong Fu; Jahar Bhattacharya; M David Tilson
Journal:  Exp Mol Med       Date:  2004-12-31       Impact factor: 8.718

6.  Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption.

Authors:  K Kusano; C Miyaura; M Inada; T Tamura; A Ito; H Nagase; K Kamoi; T Suda
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

Review 7.  Novel cardiovascular actions of the activins.

Authors:  C J Molloy; D S Taylor; J E Pawlowski
Journal:  J Endocrinol       Date:  1999-05       Impact factor: 4.286

8.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.

Authors:  F G Spinale; M L Coker; C V Thomas; J D Walker; R Mukherjee; L Hebbar
Journal:  Circ Res       Date:  1998-03-09       Impact factor: 17.367

9.  Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors.

Authors:  Y G Chen; J Massagué
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

10.  The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.

Authors:  M Kurokawa; K Mitani; K Irie; T Matsuyama; T Takahashi; S Chiba; Y Yazaki; K Matsumoto; H Hirai
Journal:  Nature       Date:  1998-07-02       Impact factor: 49.962

View more
  16 in total

Review 1.  Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch.

Authors:  Tom P Theruvath; Jeffrey A Jones; John S Ikonomidis
Journal:  J Card Surg       Date:  2011-09-29       Impact factor: 1.620

2.  Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms.

Authors:  John S Ikonomidis; Elizabeth K Nadeau; Adam W Akerman; Robert E Stroud; Rupak Mukherjee; Jeffrey A Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2016-11-14       Impact factor: 5.209

3.  Bone morphogenetic protein endothelial cell precursor-derived regulator regulates retinal angiogenesis in vivo in a mouse model of oxygen-induced retinopathy.

Authors:  Isabel Moreno-Miralles; Rongqin Ren; Martin Moser; Mary Elizabeth Hartnett; Cam Patterson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-07       Impact factor: 8.311

4.  Cellular phenotype transformation occurs during thoracic aortic aneurysm development.

Authors:  Jeffrey A Jones; Juozas A Zavadzkas; Eileen I Chang; Nina Sheats; Christine Koval; Robert E Stroud; Francis G Spinale; John S Ikonomidis
Journal:  J Thorac Cardiovasc Surg       Date:  2010-03-09       Impact factor: 5.209

5.  Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling.

Authors:  Rupak Mukherjee; William T Rivers; Jean Marie Ruddy; Robert G Matthews; Christine N Koval; Rebecca A Plyler; Eileen I Chang; Risha K Patel; Christine B Kern; Robert E Stroud; Francis G Spinale
Journal:  Circulation       Date:  2010-06-21       Impact factor: 29.690

6.  Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis.

Authors:  Mahmut Yilmaz; Dorothea Maass; Neha Tiwari; Lorenz Waldmeier; Petra Schmidt; François Lehembre; Gerhard Christofori
Journal:  EMBO J       Date:  2011-09-06       Impact factor: 11.598

7.  Connective Tissue Disorders and Cardiovascular Complications: The Indomitable Role of Transforming Growth Factor-β Signaling.

Authors:  Jason B Wheeler; John S Ikonomidis; Jeffrey A Jones
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling.

Authors:  Jeffrey A Jones; Christy Beck; John R Barbour; Jouzas A Zavadzkas; Rupak Mukherjee; Francis G Spinale; John S Ikonomidis
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

9.  TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice.

Authors:  Yu Wang; Hafid Ait-Oufella; Olivier Herbin; Philippe Bonnin; Bhama Ramkhelawon; Soraya Taleb; Jin Huang; Georges Offenstadt; Christophe Combadière; Laurent Rénia; Jason L Johnson; Pierre-Louis Tharaux; Alain Tedgui; Ziad Mallat
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

10.  Haploinsufficiency of the murine Col3a1 locus causes aortic dissection: a novel model of the vascular type of Ehlers-Danlos syndrome.

Authors:  Lee B Smith; Patrick W F Hadoke; Emma Dyer; Martin A Denvir; David Brownstein; Eileen Miller; Nancy Nelson; Sara Wells; Michael Cheeseman; Andy Greenfield
Journal:  Cardiovasc Res       Date:  2010-11-10       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.